Core Insights - NNIT has updated its financial reporting structure to consolidate all Life Sciences customers under Region Europe, US, and Asia, moving them from Region Denmark [1][2] - The restatement will be reflected in the interim report for the first nine months of 2025, scheduled for release on November 4, 2025 [2] - Historical financial figures have been restated effective from Q1 2024, impacting only Region Europe and Region Denmark, while the Group, Region US, and Region Asia remain unchanged [3] Financial Performance - For Region Europe, the restated revenue figures for Q1 2024 are DKK 175.8 million, with a gross profit of DKK 43.0 million and a gross margin of 24.5% [4] - In Region Denmark, the restated revenue for Q1 2024 is DKK 162.9 million, with a gross profit of DKK 43.8 million and a gross margin of 26.9% [6] - Revenue growth percentages before restatement for Region Europe show a range from 1.1% in Q3 2024 to 14.4% in Q4 2024, while after restatement, the range is from -4.2% in Q1 2025 to 10.6% in Q4 2024 [7] Growth Metrics - Organic growth for Region Europe before restatement was 12.2% in Q1 2024, while after restatement, it adjusted to 12.6% [7] - For Region Denmark, organic growth before restatement was 18.0% in Q1 2024, increasing to 19.7% after restatement [7] - The restated figures indicate a significant increase in revenue growth for Region Denmark, with Q1 2025 showing a growth of 5.4% after restatement compared to 4.0% before [7]

Core Insights - The IT Life Science consultancy industry is experiencing a slowdown due to geopolitical unrest, leading to lower customer engagement and project initiation [2][5] - NNIT is adapting its operating model and market strategy to focus on repeatable solutions across regions while reducing overhead costs [2][5] Financial Performance - In Q2 2025, NNIT reported revenue of DKK 462.2 million, a decline of 2.5% compared to Q2 2024, with organic growth down by 1.7% [4][5] - Group operating profit excluding special items was DKK 22.9 million, resulting in a margin of 5.0%, which is lower than the same quarter last year [4][5] - Special items for the quarter amounted to DKK 20.3 million, impacting overall profitability [4] Market Outlook - The company expects to end the full year within the lower end of the guided range for both organic growth (0% to 5%) and group operating profit margin excluding special items (7% to 9%) due to ongoing macroeconomic challenges [5] - There are early signs of improvement in demand for IT Life Science services, particularly in the US region, which has returned to growth [5]